Even as Biogen and Eisai’s Leqembi and Eli Lilly’s Kisunla slowly roll out onto the market, experts question the efficacy of ...

Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains ...

(Reuters) -Biogen expects growth of its keenly watched Alzheimer's disease drug, Leqembi, to see a "linear trend" in the ...

Biogen BIIB stock has declined 21.4% in the past three months against a decrease of 12.3% for the industry. The stock has ...

Eisai (ESALY) and Biogen (BIIB) announced that the Federal Commission for the Protection Against Sanitary Risk in Mexico has approved humanized ...

Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced that the Federal Commission for the Protection Against Sanitary Risk ...

Eisai and Biogen have reported data showing that the benefit of treatment with their Alzheimer's disease therapy Leqembi appears to build over time, with no increase in safety risks. The results ...

Eisai (ESAIY) and Biogen (BIIB) announced that the humanized anti-soluble aggregated amyloid-beta, or Abeta, monoclonal antibody Leqembi has been launched in South Korea. Leqembi received the ...

Eisai and Biogen have officially launched Leqembi (lecanemab) in South Korea, marking a significant step in Alzheimer’s ...

Analysts have recently evaluated Biogen and provided 12-month price targets. The average target is $241.79, accompanied by a ...

Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains sluggish, falling below consensus projections through 2030. Challenges ...